Thompson Philip A, Parry Erin M
Department of Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Clinical Haematology, The Royal Melbourne Hospital, Parkville, Australia; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Cancer program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Hematol Oncol Clin North Am. 2025 Jul 7. doi: 10.1016/j.hoc.2025.05.011.
Despite advances in the management of chronic lymphocytic leukemia (CLL), the transformation of CLL to an aggressive lymphoma, known as Richter transformation (RT), remains associated with dismal outcomes. Recent scientific studies deepen our understanding of the genetics and biology underlying RT. In parallel, a new era of clinical investigation is focused on improving outcomes for patients with RT, leading to the exponential increase of RT-focused trials and integration of novel targeted and immunotherapy approaches. We provide an updated biologic and clinical understanding of diffuse large B-cell lymphoma-type RT and discuss promising new therapeutic avenues for improving clinical outcomes in RT.
尽管在慢性淋巴细胞白血病（CLL）的管理方面取得了进展，但CLL转化为侵袭性淋巴瘤，即里氏转化（RT），仍然与预后不良相关。最近的科学研究加深了我们对RT潜在遗传学和生物学的理解。与此同时，临床研究的新时代专注于改善RT患者的预后，导致以RT为重点的试验呈指数级增长，并整合了新型靶向治疗和免疫治疗方法。我们提供了对弥漫性大B细胞淋巴瘤型RT的最新生物学和临床理解，并讨论了改善RT临床结果的有前景的新治疗途径。
